We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Acb4.0

Acarbose Research

Mostly mechanism / observational

180 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Acarbose studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1999–2026 with a typical study size of 240 participants.

Based on 179 studies · 11 meta-analyses · 161 RCTs · 16,248 total participants

Confidence

High confidence

By outcome

Cardiovascular & glycemicReduced cardiovascular events and progression to diabetes in people with impaired glucose tolerance · Years
Mostly mechanism / observational46 studies
Lifespan & aging (preclinical)
Mostly mechanism / observational21 studies
Safety profile
Mostly mechanism / observational4 studies

Steady research

26 studies in the last 5 years · Latest meta-analysis: 2024

199920122026

1Meta-Analysis2014

Li Y, Tong Y, Zhang Y, Huang L, Wu T, Tong N · Int J Clin Pract (2014)

Acarbose Research

Mostly mechanism / observational

Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis.

Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis.

Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.

Effects of acarbose on polycystic ovary syndrome: a meta-analysis.

Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

[Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].

The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis.

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

Acarbose Monotherapy and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An Ethnicity-specific Meta-analysis.

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review.

The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.

Influence of acarbose on blood glucose and breath hydrogen after carbohydrate load with sucrose or starch.

[A multicenter randomized controlled clinical trial on blood glucose lowering effects of domestic Acarbose (capsule) in type 2 diabetic patients].

Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial.

Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.

Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly.

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

Acarbose raises serum butyrate in human subjects with impaired glucose tolerance.

Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level.